C12Y 203/01037
5-aminolevulinate synthase
Official title: 5-Aminolevulinate synthase (2.3.1.37)
C12Y203/01037 (5-aminolevulinate synthase) appears on 15 US grants and 33 published applications in this corpus.
Search patents in C12Y- Granted patents
- 15
- Published applications
- 33
- Assignees
- 20
- Inventors
- 69
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 2 |
| 2016 | 0 | 3 |
| 2017 | 2 | 1 |
| 2018 | 2 | 1 |
| 2019 | 1 | 2 |
| 2020 | 1 | 3 |
| 2021 | 3 | 1 |
| 2022 | 0 | 4 |
| 2023 | 0 | 6 |
| 2024 | 1 | 3 |
| 2025 | 2 | 4 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Methods of treatment with aminolevulinic acid synthase 2 (ALAS2) modulators30 Jun 2026US 12,667,087 B2Agios Pharmaceuticals, Inc.
- Modulating expression of ALAS1 (5′-aminolevulinate synthase 1) gene2 Jun 2026US 12,644,123 B2Crispr Therapeutics AG
- Materials and methods for protein production30 Dec 2025US 12,509,695 B2Impossible Foods Inc.
- Production method of (R)-reticuline15 Jul 2025US 12,359,233 B2Fermelanta, Inc.
- Materials and methods for protein production23 Apr 2024US 11,965,167 B2Impossible Foods Inc.
- Ionizable lipids with linear head groups25 Jun 2026US 2026/0176283 A1Beam Therapeutics Inc.
- Chimeric transcriptional activator and use thereof25 Dec 2025US 2025/0388947 A1Nanjing Bestzyme Bio-Engineering Co., Ltd.
- Compositions and methods for inhibiting expression of the alas1 gene17 Apr 2025US 2025/0122505 A1Alnyiam Pharmaceuticals, Inc.
- Compositions and methods for inhibiting expression of the alas1 gene30 Jan 2025US 2025/0034566 A1Alnylam Pharmaceuticals, Inc.
- Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene23 Jan 2025US 2025/0027087 A1Crispr Therapeutics AG
Most cited
By later US patents
- Continuous production method for 5-aminolevulinic acid by using photosynthetic membrane vesicle15US 9,816,118 B2Sogang University Research Foundation · 2017
- Compositions and methods for inhibiting expression of the ALAS1 gene12US 9,133,461 B2Alnylam Pharmaceuticals, Inc. · 2015
- Compositions and methods for inhibiting expression of the ALAS1 gene6US 9,631,193 B2Alnylam Pharmaceuticals, Inc. · 2017
- Compositions and methods for inhibiting expression of the ALAS1 gene2US 10,119,143 B2Alnylam Pharmaceuticals, Inc. · 2018
- Compositions and methods for inhibiting expression of the ALAS1 gene2US 10,125,364 B2Alynylam Pharmaceuticals, Inc. · 2018